Abvc Biopharma, Inc.
ABVC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173313
No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.
Other share classesECOC
Q1 2024 vs. Q4 2023
How the institutions holding Abvc Biopharma, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 8 | 8 | 0 |
| Shares | 110.7K | 254.5K | +143.7K (+129.8%) |
| Value | $128.5K | $332.6K | +$204.1K (+158.9%) |
New holders (2)
Institutions that held Abvc Biopharma, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Chase Investment Counsel Corp | 178,377 | $233.0K | 0.09% |
| Bank of America Corp | 4,440 | $5.82K | 0.00% |
Sold out (2)
Institutions that held Abvc Biopharma, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Renaissance Technologies LLC | 36,100 | $42.0K |
| Citadel Advisors LLC | 27,158 | $31.5K |